More than 30% of the global population currently suffers from myopia, and that number is expected to grow to nearly 50% by 2050.1 Since Laser-Assisted In Situ Keratomileusis (LASIK) became widely available in Australia and New Zealand more than 20 years ago, the technologies have continually advanced from keratometry and refraction to corneal tomography and wavefront aberrometry, benefiting millions of patients around the world.2
Now the first fully LASIK treatment,3,4 Alcon’s wavelight plus,** is about to be available in Australia and New Zealand. To be launched at the upcoming AUSCRS congress in Hamilton Island, Alcon said its next generation wavelight plus technology unlocks a new era of precision in refractive surgery, with excellent levels of personalisation that lead to better visual outcomes with more predictability and minimal risk.4-6*
Now Alcon plans to launch the first fully LASIK treatment,3,4 wavelight plus** in Australia and New Zealand at the upcoming AUSCRS congress in Hamilton Island
By harnessing innovative ray-tracing guided tomography, the new Sightmap diagnostic device precisely creates a 3D model of the entire optical system, measuring subjective refraction and K values, wavefront, anterior cornea, pachymetry, posterior cornea, anterior chamber depth and lens position, as well as axial length.6 The measurements are done without tedious nomogram inputs, ultimately streamlining data capture and treatment planning time.
The real-world clinical evidence of 200 patients who underwent wavelight plus LASIK found that the technology delivered visual acuity results that raise the bar for refractive outcomes, which is in line with Alcon’s clinical claims.
Key results from this study7 undertaken by Dr Chandra Bala include:
• 89% of eyes achieved uncorrected distance visual acuity (UDVA) of 20/16 and 50% achieved 20/12.5 at three months,
• 98% of eyes achieved postoperative UDVA within one line of their preoperative corrected distance visual acuity (CDVA) by three months, and
• 94% of eyes achieved the same or better postoperative CDVA than their preoperative CDVA by three months.
Surgeons can find out more information about wavelight plus by visiting www.myalcon.com/professional/refractive/wavelight-refractive-suite/ or through their Alcon Sales Representative.
*Three months post-op; n=212 eyes.
**wavelight plus is the alternative equivalent tradename for InnovEyes treatment.
References
1. Holden, B.A., Fricke, T.R., Wilson, D.A., et al., Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016 May;123(5):1036-1039. doi: 10.1016/j.ophtha.2016.01.006.
2. Gelles J., Refractive technologies encompass a rapidly changing landscape. Optometry Times. Accessed October 27, 2023.
3. Kanellopoulos, A. J. (2020). Initial outcomes with customized myopic lasik, guided by automated ray tracing optimization: A novel technique. Clinical Ophthalmology (Auckland, N.Z.), 14, 3955 3963. https://doi.org/10.2147/OPTH.S280560.
4. InnovEyes Sightmap Diagnostic Device User Manual. 2023.
5. Alcon data on file, 2021. RFP911-P001 Postmarket study of outcomes from wavelight ex500 innoveyes – V-RIM-0063613.
6. Mrochen, M., Bueler, M., Donitzky, C., Seiler, T., Optical ray tracing for the calculation of optimized corneal ablation profiles in refractive treatment planning. J Refract Surg. 2008;24:S446-S451.
7. He, C., Bala, C., Ray tracing guided myopic laser in situ keratomileusis – real world clinical outcomes. J Cataract Refract Surg. 2023; doi: 10.1097/j.jcrs.0000000000001286.
